Torti, F.M., Bristow, M.R., Howes, A.E., Aston, D., Stockdale, F.E., Carter, S.K., Kohler, M., Brown, B.W.J. and Billingham, M.E. (1983) Reduced Cardiotoxicity of Doxorubicin Delivered on a Weekly Schedule. Assessment by Endomyocardial Biopsy. Annals of Internal Medicine, 99, 745-749.
https://doi.org/10.7326/0003-4819-99-6-745

has been cited by the following article:

• TITLE: The Effect of Granulocyte Macrophage-Colony Stimulating Factor upon the Induction of Peripheral Blood Dendritic and Natural Killer Cells When Given Simultaneously with a Slow Continuous Doxorubicin Infusion

  AUTHORS: Arthur J. Weiss, Irwin L. Stoloff, Antonio C. Simoes

  KEYWORDS: Doxorubicin Infusion Dendritic, Killer Cells

  JOURNAL NAME: Journal of Cancer Therapy, Vol.8 No.7, July 18, 2017

  ABSTRACT: It has been demonstrated that it is safe to give Gm-Csf, together with Doxorubicin, by continuous intravenous infusion, thereby substantially increasing the amount of Doxorubicin administered to the average patient, and assuring that each patient receives an individually-determined safe and maximal amount of drug. It is known that Gm-Csf is a potent inducer of components that are major factors in an immunologic attack upon neoplasms. For that reason, we thought it would be worth evaluating in 4 patients’ surface markers of dendritic precursor cells, dendritic cells [DC], and natural killer [NK] cells during the infusion. While there was substantial variation in individual responses, all 4 patients receiving Gm-Csf developed persistent marked increases in cells with each of these markers. The significance of these findings will be discussed.